Key result
Review highlights evolving evidence and drug choices for perioperative pharmacological cardioprotection in surgery.
Why the study?
The range of drugs recommended for pharmacological cardiac protection in high-risk surgical patients is constantly changing with new research data and guidelines.
Population
Patients with high cardiac risk undergoing non-cardiac and cardiac surgery with cardiopulmonary bypass
Design
Review including recent meta-analyses and randomized studies
Authors
Loading...
Evolving recommendations warrant updated perioperative protocols; leaves open optimal regimens pending further trials.
This review summarizes current evidence and guidelines on pharmacological cardioprotection for high-risk patients undergoing surgery.
Kozlov Ia (2019) conducted a review in High cardiac risk undergoing non-cardiac and cardiac surgery with cardiopulmonary bypass. Pharmacological cardiac protection was evaluated. The range of drugs recommended for pharmacological cardioprotection in patients undergoing cardiac and non-cardiac surgery is constantly changing in accordance with the latest data.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: